In addition, synergetic loss of BRCA1 and TRP53 may greatly induce the immune response of the mammary luminal cells and tumor cells, as compared with the Brca1 mutant cells, the Brca1/Trp53 double mutant cells, no matter luminal or tumor cells, display higher activity of immune response related pathways (Figure S6). Here, TP53 is linked to neoplasm.